stella
MelanomaSeptember 2023Summary reviewed June 2026

A Two-Drug Combination Shrank Melanoma in 28% of Previously Treated Patients

This study tested whether adding ipilimumab to nivolumab could help patients whose melanoma had grown despite initial immunotherapy. The combination slowed cancer growth better than ipilimumab alone, with 28% of patients seeing their tumors shrink compared to 9% with single-drug treatment.

What the trial was testing

The trial enrolled 94 patients with melanoma. The study was sponsored by National Cancer Institute (NCI) and tracked outcomes across the full group of patients who matched the trial's eligibility profile.

It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.

What the results showed

The combination therapy resulted in tumor shrinkage in 28% of patients whose cancer had previously resisted treatment.

Nature medicine · 2023 · NCT03033576

These findings — that patients saw their tumors shrink with the combination versus 9% with single treatment — were published in the Nature medicine and represent the headline result of the study.

Researchers tracked outcomes across 94 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.

What this means for patients

For patients with melanoma, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.

What you can do now

This was a mid-stage study in patients whose melanoma stopped responding to initial immunotherapy. Both nivolumab and ipilimumab are already FDA-approved for melanoma, though this specific combination approach for treatment-resistant cases may require discussion with your oncologist about whether it's appropriate for your situation.

Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.

Open melanoma trials

RecruitingLarge-scale testing

Perioperative Treatment With Tranexamic Acid in Melanoma

Surgery is a key element in the treatment of melanoma, and naturally linked with an inflammatory response and recruitment of innate immune cells. Although surgery has a favorable intent, surgery-induced inflammation, neutrophils in particular, may accelerate growth of local and systemic micrometastases. Thus, improving cancer surgery and modulating the wound microenvironment in ways that benefit the patients is crucial. Repurposing already approved drugs in a cancer setting has gained increasing interest in recent years. Interestingly, tranexamic acid was recently suggested as an anti-cancer drug, capable of reducing tumor growth in experimental animal models and reducing the viability of different melanoma cell lines. As a novel approach, sponsor and investigators will conduct a Randomised Clinical Trial, using perioperative treatment with Tranexamic Acid, aiming to prevent the early relapses for patients with melanoma.

Aarhus, Central Jutland, Denmark +4 more
RecruitingSafety & dosing / Early efficacy

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors. The CAR target antigen is selected for each participant after tumor profiling using a tissue biopsy and/or liquid biopsy. Participants will receive either a single-target or dual-target CAR-NK product based on the antigen profile.

Beijing, Beijing Municipality, China